Table 2 MeanVO2 peak, ventilatory threshold and fructosamine values before and after CR for each treatment group
Control treatment group (n = 31) | Intensive treatment group (n = 26) | p | |
|---|---|---|---|
Baseline VO2 peak (ml/kg/min) | 17.4 ± 4.7 | 16.5 ± 3.8 | NS |
End-CR VO2 peak (ml/kg/ min) | 20.5 ± 5.4 | 19.2 ± 5.0 | NS |
Baseline ventilatory threshold (ml/kg/min) | 12.6 ± 4.0 | 12.2 ± 3.9 | NS |
End-CR ventilatory threshold (ml/kg/ min) | 15.0 ± 5.0 | 14.3 ± 4.6 | NS |
Gain in VO2 peak (ml/kg/min) | 2.7 ± 2.8 | 2.6 ± 2.2 | NS |
Gain in ventilatory threshold (ml/kg/min) | 2.2 ± 2.4 | 2.2 ± 2.5 | NS |
Baseline fructosamine (μmol/l) | 274 ± 45 | 278 ± 52 | NS |
End-CR fructosamine (μmol/l) | 244 ± 41 | 240 ± 41 | NS |
Baseline fasting glucose (mg/dl) | 152 ± 42 | 164 ± 104 | NS |
End-CR fasting glucose (mg/dl) | 133 ± 32 | 126 ± 25 | NS |
Patients on insulin during CR | 17 (55 %) | 26 (100 %) | <0.0001 |
Mean insulin dose in insulin-treated patients (UI/day) | 38 ± 25 | 44 ± 26 | NS |
Patients on metformin during CR | 12 (39 %) | 4 (15 %) | 0.051 |